Isolated antibodies against interleukin-17 receptor B (IL-17RB) for cancer therapy

Patent metadata

Field	Value
Publication number	US-10793628-B2
Application number	US-201515322788-A
Country	US
Kind code	B2
Filing date	Jun 30, 2015
Priority date	Jun 30, 2014
Publication date	Oct 6, 2020
Grant date	Oct 6, 2020

Abstract

Methods and compositions for treatment and therapy of cancer are provided. Specifically, antagonists specific for interleukin-17 receptor B (IL-17RB) and its ligand IL-17B are provided. Potent neutralizing antibodies specific for IL-17RB and methods for their manufacture and use are disclosed. The invention also relates to antisense, RNAi and shRNA compositions for the prevention and treatment of cancer, in particular breast cancer and pancreatic cancer.

First claim

We claim:

1. An isolated antibody against interleukin-17 receptor B (IL-17RB), wherein the antibody comprises a heavy chain variable region (VH) comprising the VH CDR1-3 of SEQ ID NO:14-16, respectively; and a light chain variable region (VL) comprising the VL CDR1-3 of SEQ ID NO:17-19, respectively.

2. The isolated antibody of claim 1 , wherein the antibody comprises the VH of SEQ ID NO:12, and/or the VL of SEQ ID NO: 13.

3. The isolated antibody of claim 1 , wherein the antibody is a full-length antibody or an antigen-binding fragment thereof.

4. The isolated antibody of claim 3 , wherein the antigen binding fragment is a Fab fragment, a F(ab′)2 fragment, or a single-chain Fv fragment.

5. The isolated antibody of claim 1 , wherein antibody is a humanized antibody, a chimeric antibody, a mouse antibody or a single-chain antibody.

6. A composition, comprising the antibody against interleukin-17 receptor B (IL-17RB) of claim 1 .

7. The composition of claim 6 , wherein the composition is a pharmaceutical composition, which further comprises a pharmaceutically acceptable adjuvant and/or carrier.

8. The composition of claim 7 , which further comprises a chemotherapeutic agent.

9. A method for treating cancer in a subject, comprising administering to the subject an effective amount of the composition of claim 6 .

10. The method of claim 9 , wherein the cancer is selected from the group consisting of pancreatic cancer, breast cancer, colorectal cancer, liver cancer, kidney cancer, head and neck cancer, esophageal cancer, gastric cancer, biliary tract cancer, gallbladder and bile duct cancer, lung cancer, mammary cancer, ovarian cancer, cervical cancer, uterine body cancer, bladder cancer, prostate cancer, testicular tumor, osteogenic and soft-tissue sarcomas, leukemia, malignant lymphoma, multiple myeloma, skin cancer, brain tumor and plura malignant mesothelioma.

11. The method of claim 10 , wherein the cancer is pancreatic cancer or breast cancer.

12. The method of claim 11 , wherein the cancer is HER2 positive breast cancer or trastuzumab-resistant breast cancer.

13. An isolated nucleic acid encoding the VH and/or the VL of the antibody of claim 1 .

14. A vector comprising the nucleic acid of claim 13 .

Assignees

• Academia Sinica

Inventors

• Lee Wen-Hwa
• Shew Jin-Yuh
• Ma Che
• Chen Chia-Lin
• Lee Wen-Hsin
• Huang Chun-Kai
• Wu Heng-Hsiung

Classifications

• A61K31/713

  Double-stranded nucleic acids or oligonucleotides · CPC title

• A61K38/20

  Interleukins [IL] · CPC title

• C07K16/2866

  against receptors for cytokines, lymphokines, interferons · CPC title

• A61K2039/505

  comprising antibodies · CPC title

• C07K2317/73

  Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation · CPC title